CORONA Remedies Limited
NSE: CORONAPharmaceuticals
Share price
₹2,024.00
+1.53% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
70
out of 100 · worked out 9 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹12,346 Cr
P/E ratio
58.5
P/B ratio
16.6
ROCE
33.3%
ROE
29.6%
Dividend yield
0.5%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 16.8% a year against a sector median of 13.1% — 3.7 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 1.8 times its growth rate, on earnings growth of 33%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| CORONA Remedies Limited — this one | 33%/yr | 58.5× | ₹1.8 |
| Sun Pharmaceutical | 13%/yr | 33.4× | ₹2.6 |
| Divi's Laboratories | 13%/yr | 83.1× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 79.4× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.2× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 100.5× | ₹25.1 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 10 of 130 on returns, 33 of 127 on growth, 50 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 33.3% on capital, ahead of 92% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the 4 years of cash statements on file it made ₹679 crore of cash from the business, spent ₹645 crore on plant and equipment, and returned ₹28 crore to lenders and shareholders.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
9 of 10 checks clear · 90%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Announced 31 Jul 2026 · Consolidated
Revenue
₹422 Cr
Revenue vs last year
+21.7%
Revenue vs last quarter
+19.7%
Net profit
₹60 Cr
Profit vs last year
+30.7%
Profit vs last quarter
+33.6%
Net margin
14.2%
EPS
₹9.83
Earnings call transcript · 3 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹12,346 Cr
- Prev close
- ₹2,024.00
- 52w High
- ₹2,292
- 52w Low
- ₹1,337
- Enterprise value
- ₹12,467 Cr
- Beta
- 0.6
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 15.4%
- PEG ratio
- 1.8
- P/E ratio
- 58.5
- P/B ratio
- 16.6
- EV / EBITDA
- 39.5
- Industry P/E
- 37.6
- ROCE
- 33.3%
- ROCE 5y average
- 30.0%
- ROE
- 29.6%
- Debt / Equity
- 0.2
- Interest coverage
- 35.3
- Dividend yield
- 0.5%
- ROE 3y average
- 27.0%
- ROE last year
- 30.0%
Annual P&L
- Annual revenue
- ₹1,403 Cr
- Annual profit
- ₹185 Cr
- Operating margin
- 21.0%
- Net profit margin
- 13.2%
- EBITDA margin
- 21.0%
- Sales growth 3y
- 16.6%
- Sales growth 5y
- —
- Profit growth 3y
- 33.0%
- Profit growth 5y
- —
- EPS
- ₹30.3
- Sales growth TTM
- 18.0%
- Profit growth TTM
- 28.0%
- Dividend payout
- 33.0%
Quarter P&L
- Sales latest quarter
- ₹422 Cr
- Profit latest quarter
- ₹60 Cr
- YoY quarterly sales growth
- 21.9%
- YoY quarterly profit growth
- 30.4%
- OPM latest quarter
- 22.1%
Balance Sheet
- Book Value
- ₹122
- Face Value
- ₹10.0
- Total debt
- ₹165 Cr
- Total cash
- ₹44 Cr
- Borrowings
- ₹165 Cr
- Reserves / Equity
- 11.2
Cash Flow
- Operating cash flow
- ₹229 Cr
- Free cash flow
- ₹56 Cr
- FCF yield
- 0.4%
- Net cash flow
- -₹1 Cr
Shareholding
- Promoter holding
- 69.0%
- FII holding
- 4.2%
- DII holding
- 16.4%
- Public holding
- 10.3%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,781.00 | 33.8 | 4,27,322 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,588.00 | 85.4 | 2,54,531 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,716.20 | 80.4 | 1,79,389 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,153.00 | 23.6 | 1,15,012 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,052.80 | 101.4 | 1,10,915 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,327.20 | 30.0 | 1,07,221 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.4 | 1,03,261 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Corona Remedies | 2,041.10 | 58.8 | 12,483 | 0.49 | 60.1 | 30.1 | 422.4 | 21.9 | 33.3 |
| Median | 417.90 | 34.5 | 2,208 | 0.07 | 13.5 | 29.6 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Material Cost | 26 | 25 | 28 | 33 | ||||
| Change in Inventories | 15 | -5.70 | -7.83 | -12 | ||||
| Purchases of Stock-in-Trade | 28 | 41 | 46 | 57 | ||||
| Employee Cost | 103 | 96 | 107 | 122 | ||||
| Other Expenses | 111 | 103 | 118 | 130 | ||||
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21 | 23 | 18 | 20 | 22 | 24 | 18 | 22 |
| Other Income | 2 | 1 | 2 | 2 | 2 | -17 | 4 | 3 |
| Exceptional items (within Other Income) | 0 | -19 | 0.28 | 0 | ||||
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 44 | 61 | 70 | 55 | 55 | 80 |
| Tax % | 25 | 23 | 28 | 24 | 25 | 25 | 17 | 25 |
| Net Profit | 43 | 45 | 32 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7.03 | 7.35 | 5.16 | 7.55 | 8.55 | 6.75 | 7.41 | 9.83 |
| Diluted EPS in Rs | 8.55 | 6.75 | 7.41 | 9.83 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Expenses | 756 | 859 | 956 | 1,109 | 1,162 |
| Material Cost | 104 | ||||
| Change in Inventories | 7.05 | ||||
| Purchases of Stock-in-Trade | 150 | ||||
| Employee Cost | 403 | ||||
| Other Expenses | 446 | ||||
| Operating Profit | 128 | 156 | 241 | 294 | 317 |
| OPM % | 14 | 15 | 20 | 21 | 21 |
| Other Income | 7 | 5 | 6 | -9 | -7 |
| Exceptional items (within Other Income) | -19 | ||||
| Interest | 4 | 14 | 11 | 6.97 | 8 |
| Depreciation | 20 | 28 | 37 | 38 | 42 |
| Profit before tax | 111 | 118 | 199 | 240 | 260 |
| Tax % | 23 | 24 | 25 | 23 | |
| Net Profit | 85 | 90 | 149 | 185 | 199 |
| EPS in Rs | 14 | 15 | 24 | 30 | 33 |
| Diluted EPS in Rs | 30 | ||||
| Dividend Payout % | 20 | 25 | 30 | 33 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- 17%
- TTM
- 18%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- 33%
- TTM
- 28%
Return on equity
- 10 years
- —
- 5 years
- —
- 3 years
- 27%
- Last year
- 30%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 61 | 61 | 61 | 61 |
| Reserves | 347 | 419 | 545 | 686 |
| Borrowings | 28 | 159 | 86 | 165 |
| Other Liabilities | 159 | 191 | 237 | 293 |
| Total Liabilities | 595 | 831 | 930 | 1,205 |
| Fixed Assets | 185 | 384 | 370 | 554 |
| CWIP | 65 | 121 | 186 | 143 |
| Investments | 32 | 26 | 26 | 26 |
| Other Assets | 314 | 301 | 348 | 482 |
| Total Assets | 595 | 831 | 930 | 1,205 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from Operating Activity | 103 | 157 | 190 | 229 |
| Cash from Investing Activity | -50 | -267 | -84 | -256 |
| Cash from Financing Activity | -45 | 99 | -107 | 25 |
| Net Cash Flow | 8 | -11 | 0 | -1 |
| Free Cash Flow | 9 | -129 | 99 | 55 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 36 | 36 | 36 | 38 |
| Inventory Days | 182 | 158 | 200 | 175 |
| Days Payable | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 55 | 10 | 14 | 7 |
| Working Capital Days | 30 | -2 | 9 | -15 |
| ROCE % | 25 | 32 | 33 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
exports as % of revenue
3.00pct
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
121inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
27,23,035inr
2026-03-31
News
News and filings about CORONA Remedies Limited. Open one to see why it matters.
10 Sept, 18:05 IST · Company event · low impact
Significant increase in volume has been observed in CORONA Remedies Limited.
9 Sept, 18:05 IST · Company event · low impact
Significant increase in volume has been observed in CORONA Remedies Limited.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- active pharmaceutical ingredients (APIs)
- excipients
- finished/traded goods from third-party (loan-license) manufacturers
- lab chemicals and manufacturing consumables
- packaging materials
Buys drug ingredients from
- La Chandra Pharmalab Private Limited
Buys from
- Innova Captab Limited · CDMO — formulations contract manufacturing
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE02ZQ01018
Plants
- Corona Remedies Bhayla facility
- Corona Remedies Solan facility
News impact
Big market events that reach CORONA Remedies Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 19 Jun 2026 | unspecified | ₹10 |
|---|
Splits, bonuses & buybacks
- daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026
Bulk & block deals
| Date | Who | Bought / sold | Shares | Price |
|---|---|---|---|---|
| 17 Jun 2026 | SEPIA INVESTMENTS LIMITED | SELL | 43,28,943 | ₹1,730.00 |
| 17 Jun 2026 | HDFC MUTUAL FUND | BUY | 23,33,333 | ₹1,730.00 |
| 17 Jun 2026 | ADITYA BIRLA SUN LIFE MUTUAL FUND | BUY | 4,62,035 | ₹1,730.00 |
| 17 Jun 2026 | ABERDEEN ASIAN SMALLER COMPANIES INVESTMENT TRUST PLC | BUY | 4,50,868 | ₹1,730.00 |
Insider trades
| Disclosed | Who | Type | Shares | Value ₹ Cr |
|---|---|---|---|---|
| 19 Aug 2026 | Ranjanben Kirtisinh Parmar · Immediate Relative | BUY | 90 | 0.02 |
| 19 Aug 2026 | Ranjanben Kirtisinh Parmar · Immediate Relative | BUY | 75 | 0.02 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 50 | 0.01 |
| 19 Aug 2026 | Apurvsinh Kirtisinh Parmar · Designated Person | BUY | 50 | 0.01 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 48 | 0.01 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 43 | 0.01 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 35 | 0.01 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 6 | 0.00 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 2 | 0.00 |
| 19 Aug 2026 | Kirtisinh Manoharsinh Parmar · Immediate Relative | BUY | 1 | 0.00 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call · Q1FY273 Aug 2026
- Results presentation30 Jun 2026
- Annual report · 2025-2615 Jun 2026
- Earnings call · Q4FY2612 May 2026
- Earnings call · Q3FY263 Feb 2026
- Earnings call · Q2FY265 Jan 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.